BNP Paribas Financial Markets Acquires 73,453 Shares of Bio-Techne Co. (NASDAQ:TECH)

BNP Paribas Financial Markets increased its holdings in shares of Bio-Techne Co. (NASDAQ:TECHFree Report) by 51.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 216,174 shares of the biotechnology company’s stock after acquiring an additional 73,453 shares during the period. BNP Paribas Financial Markets owned approximately 0.14% of Bio-Techne worth $15,216,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. CVA Family Office LLC bought a new stake in Bio-Techne during the fourth quarter worth about $31,000. Mather Group LLC. bought a new stake in Bio-Techne during the first quarter worth about $38,000. First Horizon Advisors Inc. lifted its stake in shares of Bio-Techne by 57.9% in the fourth quarter. First Horizon Advisors Inc. now owns 521 shares of the biotechnology company’s stock worth $40,000 after buying an additional 191 shares in the last quarter. YHB Investment Advisors Inc. bought a new position in shares of Bio-Techne in the first quarter worth approximately $43,000. Finally, GAMMA Investing LLC bought a new position in shares of Bio-Techne in the fourth quarter worth approximately $44,000. Institutional investors own 98.95% of the company’s stock.

Bio-Techne Stock Up 0.2 %

Shares of TECH stock opened at $71.56 on Tuesday. Bio-Techne Co. has a 12 month low of $51.79 and a 12 month high of $89.91. The stock has a market cap of $11.28 billion, a P/E ratio of 56.79, a P/E/G ratio of 7.41 and a beta of 1.29. The company has a current ratio of 4.08, a quick ratio of 2.88 and a debt-to-equity ratio of 0.19. The company has a 50 day simple moving average of $76.76 and a two-hundred day simple moving average of $72.84.

Bio-Techne (NASDAQ:TECHGet Free Report) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. Bio-Techne had a net margin of 17.59% and a return on equity of 13.60%. The business had revenue of $303.43 million during the quarter, compared to analysts’ expectations of $292.36 million. During the same period in the prior year, the company earned $0.47 earnings per share. The firm’s revenue was up 3.2% on a year-over-year basis. On average, research analysts expect that Bio-Techne Co. will post 1.56 earnings per share for the current year.

Bio-Techne Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Monday, May 13th were paid a $0.08 dividend. The ex-dividend date of this dividend was Friday, May 10th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.45%. Bio-Techne’s dividend payout ratio (DPR) is presently 25.40%.

Analyst Ratings Changes

Several research analysts have recently issued reports on TECH shares. Benchmark reiterated a “buy” rating and issued a $95.00 target price on shares of Bio-Techne in a research note on Thursday, May 2nd. Robert W. Baird upped their target price on shares of Bio-Techne from $73.00 to $81.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Bio-Techne from $85.00 to $82.00 and set a “buy” rating for the company in a report on Thursday, April 18th. Finally, Citigroup cut shares of Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 price objective for the company. in a report on Wednesday, May 22nd. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.00.

Read Our Latest Research Report on Bio-Techne

About Bio-Techne

(Free Report)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

Recommended Stories

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with's FREE daily email newsletter.